Ifo-Cell N

Ifosfamide, the active ingredient in Ifo-Cell N, is an alkylating agent presented as an injection solution for intravenous use. It treats various solid tumours such as testicular cancer, soft‑tissue sarcoma, lymphoma, ovarian cancer and other malignancies in adult patients.

GNH USA supplies Ifo-Cell N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ifosfamide is an alkylating antineoplastic agent used in several solid‑tumour treatment protocols.

Testicular cancer: used in combination regimens to achieve tumour reduction and improve survival. Soft tissue sarcoma: incorporated into multi‑drug chemotherapy to shrink tumours before surgery. Lymphoma: administered as part of salvage therapy to induce remission. Ovarian cancer: employed in recurrent disease to enhance response rates. Other solid tumours: applied in selected protocols where DNA cross‑linking is beneficial.

Adverse reactions may occur with ifosfamide therapy.

Common Side Effects: - Nausea and vomiting - Fatigue and weakness - Alopecia (hair loss) - Myelosuppression (low blood counts) - Hemorrhagic cystitis (urinary irritation)

Serious or Rare Side Effects: - Nephrotoxicity (kidney damage) - Encephalopathy (neurological disturbances) - Severe infections due to immunosuppression - Secondary malignancies (e.g., leukemia) - Cardiotoxicity (heart function impairment)

Careful monitoring and supportive measures are required when using Ifo-Cell N. - Renal function: assess creatinine and ensure adequate hydration before and during therapy. - Hematologic status: perform regular complete blood counts to detect myelosuppression. - Concomitant nephrotoxic drugs: avoid or adjust dosage to reduce kidney risk. - Pregnancy: avoid use unless the potential benefit justifies the potential fetal risk. - Administration: co‑administer mesna to protect the bladder from toxic metabolites. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ifosfamide may interact with several agents, requiring vigilance.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increase risk of nephrotoxicity. - Cisplatin: additive renal toxicity may be unacceptable. - Live vaccines: immunosuppression can lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect, monitor INR. - Other myelosuppressive agents: may intensify bone‑marrow suppression. - Nephrotoxic antibiotics (e.g., vancomycin): require close renal function monitoring.